ALTEOGEN INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 174,100 KRW | -1.80% |
|
-1.58% | +76.75% |
| 2023 | Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA | CI |
| 2023 | ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
ETFs positioned on ALTEOGEN Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.64% | 2 M€ | -14.14% | ||
| 0.02% | 4 M€ | -4.41% | - | |
| 0.01% | 0 M€ | +4.12% | - | |
| 0.00% | 0 M€ | +3.44% | - | |
| 0.00% | 0 M€ | +7.83% | - | |
| 0.00% | 0 M€ | +5.52% | - | |
| 0.00% | 0 M€ | +5.36% | - | |
| 0.00% | 0 M€ | +3.45% | - | |
| 0.00% | 7 M€ | +0.11% | - |
Alteogen Inc. is a Korea-based company mainly engaged in the research and development of biopharmaceuticals. The Company operates biobetter business segment, which develops protein pharmaceuticals and cancer therapies, and bio similar business segment, which develops bio similar and animal medicines. The Company mainly provides growth hormone, herceptin, humira, antibodies, animal drugs and others.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
174,100
KRW
Average target price
220,000
KRW
Spread / Average Target
+26.36%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +76.75% | 6.76B | |
| -3.35% | 88.91B | |
| +4.08% | 41.25B | |
| -14.72% | 31.99B | |
| +51.33% | 24.73B | |
| -14.74% | 15.54B | |
| -40.39% | 12.07B | |
| -8.63% | 12.05B | |
| -14.99% | 12.02B | |
| +6.22% | 8.84B |
- Stock Market
- Equities
- A196170 Stock
- Funds and ETFs ALTEOGEN Inc.